4 курс / Акушерство и гинекология / Практическая_кольпоскопия_Роговская_С_И_

47..

. — 2- . - .: , 2008.

48.., ., ., .

// . — 2002. — 6.

49.. : . . . .

. . — , 1996.

50.., ., .

: . —

, 2007.

51..

,

: . .... . . . — ., 2006.

52.. .

// . — 2005. —

3. — . 17-20.

53.., .

. - , 2006.

54.., ., .

. — ; ., 1997.

55.. ., . :

// Terra Medica. — 2001. — 4.

56.., ., .

- : . — .: , 2008. — 400 .

57.., .

. — .: , 2009.

58.., ., .

// . . - 1999. - 5. - .61-65.

59.. ., .

. — ., 2008.

60.Almonte ., Ferreccio ., Winkler J.L., Cuzick J., Tsu V., Robles S., Takashashi R., Sasieni P. (2007) Cervical screening by visual inspection, HPV testing, liquid-based and conventional cytology in Amazonian Peru. Int J Cancer 121: 796—802.

61.American Cancer Society Guidline for early detection of cervical neoplasia and cancer / CA Cancer Clin 2002, 52. - P. 342-362.

62.Apgar ., Cox T. Differentiating normal and abnormal findings of the vulva // Am. Fam.Phys. - 1996. - Vol. 32. - P. 1171-1184.

63.Arbyn M., Primic-Zakelj M., Raifu A.O., Grce M., Paraskevaidis E., Diakomanolis E., Kesic V., Nicula F.A., Suteu O., von Karsa L. The burden of cervical cancer in south-east Europe at the beginning of the 21 st century.Coll Antropol. 2007 Apr.; 31 Suppl 2: 7—10.

64.Arbyn M., Sasieni P., MeijerC.J., ClavelC., KoliopoulosG., DillnerJ.

(2006) Chapter 9: Clinical applications of HPV testing: a summary of metaanalyses. Vaccine 24 (Suppl 3): S 78—S 89.

65.Arany I., Nagamani K, Tyring S.K. Interferon resistance is independent from copy numbers in benign HPV induced lesions // Anticancer. Res.

—1995. — Vol. 15. — 3. — P. 1003-1006.

66.Ault K.A., Friese A'., Gissmann L. et at. Recommendations for the Diagnosis and Treatment of HPV Infections of Female Tract, European J for Infectious Diseases in Obstetrics and Gynecology, 2002 (available also at www.esidog.com).

67.Brown D.R., Wang G„ Safran M.A. A Preliminary analysis of medical expenditures among active and sedentary US adults with mental disorders.Am J Health Behav. 2005 May-Jun; 29(3): 195-205.

68.Blanc ., Benmoura D. / Colposcopie et pathologie genitale. — Paris, 1993.

69.Boonstra H. et al. Obstetrics & Gynecology, 1990. 75 (2): P. 227-231

70.Bosch F.X. et al. British Journal of Cancer (2008) 98 (1), 15-21 & 2008 Cancer Research UK.

71.Byrom J., Douce G., Jones P.W., Tucker H., Millinship J., Dhar K, Redman C.W. Should punch biopsies be used when high-grade disease is suspected at initial colposcopy assessment? A prospective study. Int J Gynecol Cancer. 2006 Jan— Feb;16(l): 253-6.

72.Cartier R. Practical Colposcopy. — New-York, 1984.

73.ho H., Kim M.K., Lee J.K., Son S.K., Lee K.B., Lee J.M., Lee J.P., Hur S. Y., Kim J.H. Relationship of serum antioxidant micronutrients and sociodemographic factors to cervical neoplasia: a case-control study. Clin Chem Lab Med. 2009 Jul 10.

74.Centers for Disease Control and Prevention (2007) Quadrivalent Human Papillomavirus Vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). http://www.cdc.gov/mmwR/preview/mmwrhtml/rr56e312al. htm 56:1-24.

75.Comprehenisve Cervical Cancer Control A guide to essential practice.

—, 2006.

76.CoxJ. T. Clinical role of HPV testing // Obstet. Gynecol. Clin. North. Am. — 1996. - Vol. 23. - 4. - P. 811-851.

77.Coppleson M. Colposcopic features of papillomavirus infection / Gynaecological Oncol / Vol 1, 2nd ed. Churchil Livinstone, Edinburg, 1992. - P. 303.

78.Cortes J.R., Arratia J., Martinez R., Gomez L. [Extensive condyloma acuminata of the penis successfully treated with 5% imiquimod cream] Actas Urol Esp. 2007 Mar;31(3): 276-8. Spanish.

79.Cuzick J., Mayrand M.H., Ronco G., Snijders P., Wardle J. (2006) Chapter 10: New dimensions in cervical cancer screening. Vaccine 24 (Suppl 3): S 90—S 97.

80.Cuzick J., ClavelC., PetryK.U., MeijerC.J., HoyerH., Ratnam S., SzarewskiA., Birembaut P., Kulasingam S., Sasieni P., Iftner T.

(2006) Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 119: 1095-1101.

81.Dallenbach-HellwegG., Knebel-DoeberitzM., Trunk M.J. Color atlas of histopathology of cervix uteri, 2004.

82.Luesly D., Shaft M., Jordan J. Handbook of Colposcopy, 1996.

83.Davis G.D. Colposcopic examination of vagin // Obst.Gyn.Clin.-Am., 1993, Mar. 20(1), 217.

84.Davison J., Marty J. Detecting premalignant cervical lesions: contribution of screening colposcopy to cytology // Jorn. repr. Med. — 1994. — 5. — P. 408-410.

85.Denny L., Quinn M., Sankaranarayanan R. (2006) Chapter 8: Screening for cervical cancer in developing countries. Vaccine 24 (Suppl 3): S 71—S 77.

86.Dexeus S. Colposcopy carried out by experts in multidisciplinary teams provides the best results. Cytopathology. 2008 Dec; 19(6): 337-8.

87.Dunne E.F., Unger E.R., Sternberg M., McQuillan G., Swan D.C., Patel S.S., Markowitz L.E. (2007) Prevalence of HPV infection among females in the United States. JAMA 297: 813-819.

88.EAGC Course Book on Colposcopy. Edited by P. Bocze, D.M. Luesley / Primed-x Press, Budapest, 2003.

89.Elbasha E.H., Dasbach E.J., Insinga R.P. (2007) Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 13: 28—41.

90.Einstein M.H., Schiller J. ., Viscidi R.P., Strickler H.D., Coursaget P., Tan ., Halsey N., Jenkins D. Clinician's guide to human papillomavirus immunology: knowns and unknowns. Lancet Infect Dis. 2009 Jun; 9 (6): 347-56.

91.FambriniM., Penna C., PieralliA., FallaniM.G., Andersson K.L., Lozza V., Scarselli G., Marchionni M. Carbon-dioxide laser vaporization of the Bartholin gland cyst: a retrospective analysis on 200 cases. J. Minim Invasive Gynecol. 2008 May-Jun; 15 (3): 327-31.

92.Fambrini M., Penna C., Fallani M.G., PieralliA., Mattel A., Scarselli G., Taddei G.L., Marchionni M. Feasibility and outcome of laser C02

conization performed within the 18th week of gestation.Int J Gynecol Cancer. 2007 Jan-Feb; 17 (1): 127-31.

93.Ferenczy A., Winkler B. Cervical intraepithelial neoplasia and condylo-ma // Blausteen's Pathology of the Female Genital Tract / Ed. R.J.Kurman. — N.Y.: Springer Verlag. — 1989. — P. 184-191.

94.Franco E.L., Duarte-Franco E., Ferenczy A. Cervical cancer: Epidemiology, prevention, and role of HPV// Canadian Med. Acc. J. — 2001. — Vol. 164. — 7.-P. 1017-1024.

95.Franco E.L., Cuzick J., Hildesheim A., de Sanjose S. (2006) Chapter

20:Issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine 24 (Suppl 3): S 171—S 177.

96.FrazerJ.H. et al. The Pediatric Infectious Dis J., Vol 25. - 2. - C. 65-81.

97.FregaA., StentellaP., DelorisA., PiazzeJ.J., FambriniM., MarchionniM., CosmiE.V. Young women, cervical intraepithelial neoplasia and human papillomavirus: risk factors for persistence and recurrence. Cancer Lett. 2003 Jul 10; 196 (2): 127—34.

98.Ganse R. Einfunrung in die Kolposkopie. — Jena, 1963.

99.Garland S.M., Hernandez-Avila M., Wheeler C.M., Perez G., Harper D.M., etc Koutsky L.A. (2007) Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356:1928-1943.

100.Global Advisory Committee on Vaccine Safety (GACVS) (2007) http:// www.who.

101.int/vaccine safety/en.

102.Goldie S.J., Kim J.J., Kobus K., Goldhaber-Fiebert J.D., Salomon J., O'shea M.K.

103.Xavier B.F., de Sanjose S„ Franco E.L. (2007)

Cost-effectiveness of HPV 16,18 vaccination in Brazil. Vaccine 25(33): 6257—6270.

104.GrammerH. Die Kolposcopie in der Praxis. — Stuttgart, 1987.

105.Gross and Barraso (eds.) Human papilloma virus infection: a clinical atlas // Berlin; Wiesbaden: Ullstein Mosby, 1997. — 300 p.

106.Guerrero E., Daniel R. W., Bosch F.X. et al. Comparison of ViraPap, Southern Hybridization, and Polymerase Chain Reaction methods forHuman Papillomavirus identification in an epidemiological investigationof cervical cancer // J. Clin. Microbiol. - 1992. - Vol. 30. - P. 2951.

107.Guidelines 2002 for treatment of sexually transmitted diseases.CDC. Alanta. USA.

108.Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.B., Romanowski ., RoteliMartins C.M., Jenkins D., Schuind A., Costa Clemens S.A., Dubin G. (2006) Sustained efficacy up to 4.5 years of a

bivalent LI virus-like particle vaccine against human papillomavirus types 16 and 18: followup randomised control trial. Lancet 367: 1247-1255.

109.Herrero R., Castellsague X., Pawlita M. et al. J Natl Cancer Inst. 2003; 95: 17721783.

110.Hiidesheim A., Herrero R., Wacholder S., Rodriguez A.C., Solomon D., Bratti M.C., Schiller J. ., Gonzalez P., Dubin G., Porras C., Jimenez S.E., Lowy D.R. (2007) Effect of human papillomavirus 16/18 LI viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 298: 743-753.

111.Hillemanns P., WangX., HertelH., Andikyan V., Hillemanns M., Stepp H., Soergel P. Pharmacokinetics and selectivity of porphyrin synthesis after topical application of hexaminolevulinate in patients with cervical intraepithelial neoplasia. Am J Obstet Gynecol. 2008 Mar; 198 (3): 300.el-7. Epub 2008 Feb. 21.

112.International Agency for Research on Cancer (2005) IARC Handbooks of Cancer Prevention. Cervix Cancer Screening. Lyon: IARC Press.

113.Ishikawa M., Fujii ., Saito M., Nindl J., Ono A., Kubushiro K, Tsukazaki K., Mukai M., Nozawa S. Performance of human papillomavirus (HPV) DNA and mRNA testing strategies in women with and without cervical neoplasia. Int J Gynecol Cancer. 2006 Jan-Feb; 16(1): 347-53.

114.Jordan J., Martin-Hirsch P., Arbyn M., Schenck U., Baldauf J.J., Da Siha D., AnttilaA., Nieminen P., Prendiville W. European guidelines for clinical management of abnormal cervical cytology, part 2.Cytopathology. 2009 Feb; 20(1): 5-16.

115.Julian . A Manual of Clinical Colcoscopy // The Pathenton Publishing Group Inc. — 1998. IARC cervix cancer screening meeting 20—27 Apr., 2004.

116.Jonassen C.M., Trope A., Sjeborg K., EskildA., Cuschieri K., Eriksen ., Thoresen S., Steinbakk M., Laurak V., Westerhagen U., Jacobsen M.B., Lie A.K. RNA ( 6/ E7) versus DNA (E6/E7) assays for risk evaluation in women infected with Human Papillomavirus (HPV). Int J Gynecol Cancer. 2007 Jan-Feb; 17(1): 127-31

117.Kanodia S., Da Silva D.M., Kast W.M. Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions. Int J Cancer. 2008 Jan 15; 122(2): 247-59.

118.Kesic V., Dokic M., Atanackovic J., Milenkovic S., Kalezic I., Vukovic S. Hysterectomy for Treatment of CIN. J. Low Genit Tract Dis. 2003 Jan; 7(1): 32-5.

119.Kesic V., Jovicevic-Bekic A., Vujnovic M. Cervical cancer screening in Serbia. Coll Antropol. 2007 Apr.; 31 Suppl 2: 31-6.

120.Khan A.M., Singer A. Biomarkers in cervical precancer management: the new frontiers. Future Oncol. 2008 Aug.; 4(4): 515-24. Review.

121.KimJ.J., WrightT.C., GoldieS.J. (2005) Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands France, and Italy. J Natl Cancer Inst 97: 888-895.

122.Kitchener H.C., Castle P.E., Cox J.T. (2006) Chapter 7: Achievements and limitations of cervical cytology screening. Vaccine 24 (Suppl 3): S 63—S 70.

123.KjaerS., Rogdall E., Frederiksen ., Munk C., van den Brule A., Svare E., MeijerC., LorinczA., Iftner T. (2006) The absolute risk of cervical abnormalities in high-risk human papilloma virus-positive, cytologically normal women over a 10-year period. Cancer Res 66(21): 10630-10636.

124.Knebel-Doebaritz M., Spitkovskky, RidderK. Interaction between steroid hormones and viral oncogenes in the pathogenesis of cervical cancer // Verch. Dtsch. Ges. Pathol. - 1997. - Vol. 81. - P. 233-239.

125.Klaustermeier O. et al. Newsletter on HPV. — 2005. — 6,

Apr.

126.Kolsted P., StaflA. Atlas of Colposcopy (3rd ed). Oslo: Universitetsforlaget, 1982.

127.Kyrgiou M., Koliopoulos G., Martin-Hirsch P., Arbyn M., Prendiville W., Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta analysis. The Lancet, 2006; 367: 489-498.

128.Koushik A., SchafferA.,, Trottier //., Duarte-Franco E., Mansour N., Arseneau J., Provencher D., Gilbert L., Gotlieb IV., Ferenczy A., Coutlee F., PollakM.N., Franco E.L. Biomarkers of Cervical Cancer Risk Study Team. Insulin-like growth factor-I and risk of high-grade cervical intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev. 2007 Apr; 16 (4): 716-22.

129.Laslo Szalay, Ungar L. Cervical Pathology. Colposcopy and Cytology. Tutorial. Cytosza Publishing, Gybr, Hungary, 2007. — 444 p.

130.LieA.K. et. al. (2005) DNA versus RNA based methods for human papillomavirus detection cervical neoplasia. Gyn Oncol, Vol 97, Issue 3 , June 2005, 908-915.

131.Lozowski M.S., Yousri M., Tulebain F. et al. The combined use of cytology and colposcopy in enhancing diagnostic accuracy in preclinical lesions of the uterine cervix. Acta Cytol. - 1982; 26: 285-91.

132.Mandelblatt J. Cervical cancer screening in primary care: Issues and recommendations. Prim Care 1989; 16: 133-55.

133.Matejic ., Kesic V., Markovic M., Topic L. Communications about cervical cancer between women and gynecologists in Serbia. Int J Public Health. 2008; 53 (5): 245-51.

134.Maclean ., Jones R. W., Scurry J., Neill S. Vulvar cancer and the need for awareness of precursor lesions.J Low Genit Tract Dis. 2009 Apr.; 13(2): 115—7.

135.Mayeaux E.J. et al. Placebo-controlled trial of Indol-3-carbinol in treatment of CIN. Gynecol Oncol 2000 Aug; 78(2) - P. 123-129.

136.MajewskiS., Bosch F.X., DillnerJ., Iversen O.E., KjaerS.K., MunozN., Olsson S.E., Paavonen J., Sigurdsson K., Bryan J., Esser M.T., Giacoletti K., James M., Taddeo F., Vuocolo S., BarrE. The impact of a quadrivalent human papillomavirus (types 6, 11, 16, 18) virus-like particle vaccine in European women aged 16 to 24.J Eur Acad Dermatol Venereol. — 2009 Apr 23.

137.Management of a patient with an abnormal cervical smear, clinical practice guidelines, Economic Evaluation Department, France, 2002.

138.Martin-Hirsch P., Rash ., Martin A., Standaert B.

Management of women with abnormal cervical cytology: treatment patterns and associated costs in England and Wales.BJOG. 2007 Apr; 114(4): 408-15.

139.Mayrand M.H., Duarte-Franco E., Rodrigues L, Walter S.D., HanleyJ., Ferenczy A., Ratnam S., Coutle e F., Franco E.L., for the Canadian Cervical Cancer Screening Trial Study Group (2007) Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med357:1579— 1588.

140.McCord M.L., Stovall T.G., Summitt R.L., Ling F.W.

Discrepancy of cervical cytology and colposcopic biopsy: Is cervical conization necessary? Obstet Gynecol 1991; 77: 715-9.

141.Meisels A., Morin C. Flat condylomata of cervix: two variants with different prognosis // Viral Cytology of Cervical Cancer (Banbury Report 21) // Eds. R. Peto, zur H. Hausen - N.Y.: Cold Spring Press. - 1986. - P. 115-119.

142.Melnikow J. Natural history of cervical squamous intraepithelial lesions: A meta_ analysis // Obstet Gynecol 1998 - Vol. 92. - P. 727-735.

143.Mestwerdt G. Atlas de colposcopie. — Paris, 1955.

144.MitchellM.F., SchottenfeldD., Tortolero-Luna G., CantorS.B., Richards-Kortum R. Colposcopy for the diagnosis of squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol. 1998 Apr; 91(4): 626-31.

145.Monsonego J., Munoz N., Manalastas R. Jr., Pitisuttithum P., Tresukosol D., Ault K, Clavel C., Luna J., Myers E., Hood S., Bautista

O., Bryan J., Taddeo F.J., Esser M.T., Vuocolo S., Haupt R.M., Barr E., Saah A. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet. — 2009 Jun. 6; 373 (9679): 1949-57.

146.Monsonego J. Emerging issues on HPV infections from science to practice. Karger AG. - 2006, P. 275.

147.Morchetti S., Cattani P., Siddu A., D'Onghia Santangelo R., Vellone V.G., Zannoni G.F., Fadda G.J. Clin Microbiol. — 2009, Apr.

148.Miinger K, McLaughlin-Drubin MEOncogenic activities of human papillomaviruses. Virus Res. — 2009, Jun 18.

149.Olsson S.E., Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Malm C., Iversen O.E.,Hoye J., Steinwall M., Riis-Johannessen G., Andersson-Ellstrom A.,Elfgren K, von Krogh G., Lehtinen M., Paavonen J., Tamms G.M., Giacoletti K., Lupinacci L., Esser M.T., Vuocolo S.C., Saah A. J., Barr E. (2007) Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 LI virus-like particle (VLP) vaccine. Vaccine 25: 49314939.

150.Paavonen J., NaudP., Salmeron J., Wheeler C., Chow S.N., Apter D., Kitchener H., Castellsague X., Teixeira J., Skinner S., Hedrick J., Jaisamrarn U., Limson G., GarlandS., Szarewski A., Romanowski ., AokiF., Schwarz ., Poppe W., Bosch F., Jenkins D., Hardt K, Zahaf ., Descamps D., Struyf F., Lehtinen M., Dubin G.; for the HPV PATRICIA Study Group. Efficacy of human papillomavirus (HPV)- 16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.: Lancet. — 2009, Jul .6.

151.Parazzini F, Vecchia C., Negri H. Oral contraceptive and invasive cervical cancer 11 Im J Epidemic!. - 1999. - P. 259-263.

152.Peckham ., Greene R. Follow-up of cervical epithelial abnormalities. Am J Obstet Gynecol. - 1957; 74: 804-815.

153.Petry . V., Breugelmans J.G., BenardS., Lamure E., LittlewoodK.J., Hillemanns P. Cost of screening and treatment of cervical dyskaryosis in Germany. Eur J Gynaecol Oncol. - 2008; 29(4): 345-349.

154.Plante M. Vaginal radical trachelectomy: an update. Gynecol Oncol. 2008 Nov; 111 (2 Suppl): S105-10.

155.Prevention of genital papillomavirus infection. Report to Congress, CDC, 2004.

156.Pretorius R.G., Zhang W.H., Belinson J.L., Huang M.N., Wu L.

., Zhang X., Qiao Y.L. Colposcopically directed biopsy, random

cervical biopsy, and endocervical curettage in the diagnosis of cervical intraepithelial neoplasia II or wors Am J Obstet Gynecol. - 2004, Aug; 191(2): 430-4.

157.Quereux C., Hourdequin P., Saniez D. Patologie lu col et immunodepression I j Contrac. fert. sex 1994. - 12. - P. 771-776.

158.Raffle A.E. (2007) Challenges of implementing human papillomavirus (HPV) vaccination policy. BMJ 335: 375—377.

159.RegiA., Krishnaswami H., Sairaj P. Management of patients with midly dysplastic cervical smears \\orn. repr. med. — 1994. —

6.— P. 455—458.

160.Reid R., Campion M.J. HPV-associated lesions of the cervix: Biology and colposcopic features. Clin Obstet Gynecol. — 1989; 32: 157—179.

161.Reid R, Scalzi P. Genital warts and cervical cancer. VII. An improved colposcopic index for differentiating benign papillomaviral infections from high-grade cervical intraepithelial neoplasia. Am J Obstet Gynecol. — 1985; 153: 611-618.

162.Ross J.D. Is oral contraceptive associated with genital warts? Genitourin Med. — 1996, Oct; 72(5): 330-3.

163.Russomano F., Re is A., Camargo M. et al. Efficacy in treatment of subclinical cervical HPV infections without CIN. Systemic review. SanPaulo Mtd J // Rev Paul Med. - 2000. - Vol. 118. -4. - P. 109-115.

164.Sankaranarayanan R., Okkuru Esmy P., Rajkumar R., Muwonge R., Swaminathan R., Shanthakumari S., Fayette J.M., Cherian J. (2007) Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial. Lancet 370: 398-406.

165.Sankaranarayanan R. Thara S., Esmy P.O., Basu P. Cervical cancer: screening and therapeutic perspectives. Med Princ Pract. — 2008; 17(5): 351—364.

166.Schiffman M., Castle P.E. (2005) The promise of global cervical-cancer prevention. N Engl J Med 353: 2101-2104.

167.Seresini S., Origoni M., Lillo I7., Caputo L., Paganoni A.M., Vantini S., Longhi R., Taccagni G., Ferrari A., Doglioni C., Secchi P., Protti M.P. IFN-gamma produced by human papilloma virus-18 E6-specific CD4+ T cells predicts the clinical outcome after surgery in patients with high-grade cervical lesions. J. Immunol. — 2007, Nov 15;

179(10): 7176-83.

168.Shaft M., Naseer S. Colposcopy. A practical guide. — Fivepin ltd. — 2006.

169.Shakuntala Baliga Colposcopy colour atlas. India, Deli, 2006.

170.Shepherd R., Weston J., Peersman G., Napuli I.Z.

Interventions for encouraging sexual lifestyles and behaviours inteded to prevent cervical cancer I j Cochrane Library, Issue, 2000a. Oxford: Update Software. - 150 p.

171.Sideri ., Jones R.W., Wilkinson E.J. et. al. Squamous vulvar intraepithelial neoplasia — 2004 modified terminology, ISSVD oncology subcommittee. J Rep Med. - 2005; 50; 807-810.

172.Singer A., Monaghan J.M. Lower Genital Tract Precancer 11 Colposcopy, 1994.

173.Singer A. et al (2003) A real time opiticoelectronic device as an adjunct to the Pap smear in cervical screening. A multicenter trial. Int. J. Gynaecol Cancer 13: 804- 811.

174.Snoeck R. Papillomavirus and treatment.Antivir rec. — 2006; 71 (2-3); 181.

175.Socolov D., Anton G., Anton A.C., Anton E., Socolov R. V., Teleman S., Melinte A Boiculese L., Stoian M. Electrosurgical loop excision/conisation for cervical intraepithelial neoplasia in an algorithm that excludes punch biopsy — a study of 210 cases.Chirurgia (Bucur). - 2009 May-Jun; 104(3): 295-301.

176.Spitzer M. Screening and management of women and girls with human papillimavirus infection/ Gynecologic oncology/ Vol. 107.

— 2. — suppll. — Nov 2007, S 14-19.

177.SjeborgK., Trope A., EskildA., CuschieriK., Eriksen ., ThoresenS., Steinbakk M., Laurak V, Jonassen C.M., Westerhagen U., Jacobsen M.B., Lie A.K. Performance of human papillomavirus (HPV) DNA and mRNA testing strategies in women with and without cervical neoplasia. J Clin Microbiol. — 2009, Jun 17.

178.Stanley M. HPV vaccines: are they the answer? Br Med Bull. 2008; 88(1): 59-74. Epub. — 2008, Oct. 21. Review.

179.Steben M., Duarte-Franco E. Human papillomavirus infection: epidemiology and pathophysiology.Gynecol Oncol. — 2007 Nov; 107(2 Suppl): S 2-5. Review.

180.Stellato G., Paavonen J. Vulvar and vag.colposcopy // Eur.J.GynOncol.,1995,16(3)228.

181.Trushina O.I., Novikova E.G., Sokolov V. V., Filonenko E. V., Chissov V.I., Vorozhtsov GN. Photodiagnosis Photodyn Ther. - 2008, Dec; 5(4): 256-259.

182.The TOMBOLA (Trial Of Management of Borderline and Other Low-grade Abnormal smears) Group After-effects reported by women following colposcopy, cervical biopsies and LLETZ: results from the TOMBOLA trial. BJOG. — 2009, Jul. 7.

183.Verguts J., Bronselaer ., Donders G., Arbyn M., Van Eldere J., Drijkoningen M., Poppe W. Prediction of recurrence after treatment